Regulatory approval

Published by the Health Service Executive. Approved

Extended adjuvant treatment of hormone-dependent-invasive breast cancer in postmenopausal women who have received prior adjuvant endocrine therapy for 5 years.

This is written in the approval document.

Reimbursement

CDS

Citation

Letrozole Monotherapy, 2026, version number 4, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6817/371_Letrozole_.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	ER positive, PR positive	Invasive Breast Carcinoma	Letrozole
HSE (1)	ER positive	Invasive Breast Carcinoma	Letrozole
HSE (1)	PR positive	Invasive Breast Carcinoma	Letrozole